Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double Blind, Controlled Study to Evaluate the Safety and Efficacy of PROSTVAC®-VF/TRICOM™ in Combination With GM-CSF in Patients With Androgen-Independent Adenocarcinoma of the Prostate

NCT00078585 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT00078585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00078585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double Blind, Controlled Study to Evaluate the Safety and Efficacy of PROSTVAC®-VF/TRICOM™ in Combination With GM-CSF in Patients With Androgen-Independent Adenocarcinoma of the Prostate
Lead sponsor
Bavarian Nordic
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2003
Completion date
January 31, 2009
Enrollment
120
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer